The target protein for the DRUGMATRIX assay is the homologous single protein which inhibits Monoamine Oxidase MAO-A enzyme using Kynuramine as a substrate. The assay cell type is BTI-TN-5B1-4 with an in vitro test type and a binding assay type description. Does this molecule show efficacy in this assay?